MeSH D000236 - adenoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009375:Glandular and epithelial neoplasms
0 Companies
0 Drugs
Success rate
D000236:Â
Adenoma
D000237:Basophil adenoma
0 Companies
0 Drugs
Success rate
D000238:Chromophobe adenoma
0 Companies
0 Drugs
Success rate
D000239:Acidophil adenoma
0 Companies
0 Drugs
Success rate
D000314:Adrenal rest tumor
0 Companies
0 Drugs
Success rate
D001079:Apudoma
0 Companies
0 Drugs
Success rate
D002759:Bile duct adenoma
0 Companies
0 Drugs
Success rate
D003537:Cystadenoma
0 Companies
0 Drugs
Success rate
D006607:Sweat gland adenoma
0 Companies
0 Drugs
Success rate
D007516:Islet cell adenoma
0 Companies
0 Drugs
Success rate
D008654:Mesothelioma
D008949:Pleomorphic adenoma
0 Companies
0 Drugs
Success rate
D015175:Prolactinoma
0 Companies
0 Drugs
Success rate
D018248:Liver cell adenoma
0 Companies
0 Drugs
Success rate
D018249:Oxyphilic adenoma
0 Companies
0 Drugs
Success rate
D018253:Villous adenoma
0 Companies
0 Drugs
Success rate
D018254:Adenomatoid tumor
0 Companies
0 Drugs
Success rate
D018255:Pulmonary adenomatosis
0 Companies
0 Drugs
Success rate
D018256:Adenomatous polyps
0 Companies
0 Drugs
Success rate
D049912:Growth hormone-secreting pituitary adenoma
0 Companies
0 Drugs
Success rate
D049913:Acth-secreting pituitary adenoma
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Cabergoline | Cabergoline |  | 2007-03-07 |  |  |
| Octreotide | Octreotide |  | 2023-12-05 |  |  | |
| Padagis | Bromocriptine | Bromocriptine |  | 2008-10-01 |  |  |
| Ingenus | Cabergoline | Cabergoline |  | 2018-08-01 |  |  |
| Mylan | Bromocriptine | Bromocriptine |  | 2005-04-04 |  |  |
| Cabergoline | Cabergoline |  | 2013-12-02 |  |  | |
| Octreotide | Octreotide |  | 2011-02-10 |  |  | |
| Sandoz | Bromocriptine | Bromocriptine |  | 1998-01-13 |  |  |
| Novartis | Octreotide | Sandostatin |  | 1988-10-21 | $1,265 M | Q2/22-Q2/25 |
| Pfizer | Cabergoline | Dostinex |  | 1996-12-23 |  |  |
| Zydus Therapeutics | Bromocriptine | Bromocriptine |  | 2008-07-30 |  |  |
| Sun Pharmaceutical Industries | Octreotide | Octreotide |  | 2008-03-04 |  |  |
| Apotex | Cabergoline | Cabergoline |  | 2013-03-08 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/1
Phase 2
100%6/6
Phase 3
45%5/11
Approved: 4Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use